sterna biologicals

About sterna biologicals

Sterna Biologicals is a clinical-stage immunology company focused on developing novel treatments for chronic inflammatory diseases. The company operates in the biopharmaceutical market, targeting conditions such as asthma, ulcerative colitis, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. Sterna Biologicals primarily serves patients with high unmet medical needs, offering potential first-in-class anti-inflammatory treatments. The business model revolves around advancing its proprietary therapies through clinical trials and eventually bringing them to market. Revenue generation is expected through the commercialization of these therapies, either independently or via partnerships with larger pharmaceutical companies. The company has completed multiple phase IIa clinical trials with topical formulations of its lead candidate, hgd40, demonstrating promising results. Sterna Biologicals leverages its expertise in immunology to downregulate GATA 3, a key transcription factor in chronic inflammation, aiming to provide effective and innovative treatment options.